ACCG-2671
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
Aconcagua Bio, Inc · Phase 1/2 · Recruiting · Enrollment 164
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Part 1 (SAD) | n/r | n/r | n/r | n/r | n/r |
| Placebo Part 1 (SAD) | n/r | n/r | n/r | n/r | n/r |
| Part 2 (Food-effect) | n/r | n/r | n/r | n/r | n/r |
| ACCG-2671 Part 3 (MAD) | n/r | n/r | n/r | n/r | n/r |
| Placebo Part 3 (MAD) | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.